abstract |
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin α v β 3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of α v β 3 -mediated disorders, such as restenosis, in human patients. |